



Dolutegravir


DTG 50mg




DTG 50mg (Scored)




DTG 50mg DT




TDF/3TC/DTG




TDF/FTC/DTG



TAF/FTC/DTG




Dolutegravir: Filing analysis




*Country filing plans with dates are usually finalized close to or after SRA/WHO PQ filing. Hence this data will become richer as further SRA/WHO PQ filings happen

Generic DTG has been filed in 26 countries, of which approval is received from Kenya and India.
Another 38 filings planned by end of 2017

DTG 50mg: Percentage Coverage of PLHIV in LMICs




Current filing plan addresses 95% of all PLHIVs effectively covered in the licence by end of 2017



*Country filing plans with dates are usually finalized close to or after SRA/WHO PQ filing. Hence this data will become richer as further SRA/WHO PQ filings happen

Generic TDF/3TC/DTG has been filed in 11 countries, and another 22 filings planned by end of 2017



Current filing plan addresses 90% of all PLHIVs effectively covered in the licence by end of 2017

Other Formulations